Thursday, 25 April 2024
Eyegate Pharmaceuticals Inc
02:30 | 10/3/18
GlobeNewswire
WALTHAM, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and ...
more»
09:26 | 9/3/18
Simply Wall St
EyeGate Pharmaceuticals Inc's (NASDAQ:EYEG) most recent earnings update in December 2017 suggested company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below is a brief commentary on my key ...
more»
10:22 | 3/3/18
GlobeNewswire
EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products using its two proprietary platform technologies for treating diseases and disorders of the eye.
more»
23:18 | 21/2/18
Frisco Fastball
Analysts expect Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report $-0.25 EPS on February, 22.They anticipate $0.13 EPS change or 34.21 % from last quarter's $-0.38 EPS.
more»
02:30 | 8/2/18
GlobeNewswire
These “forward-looking” statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate's products, including EyeGate's EGP-437 combination product ...
more»
10:10 | 7/2/18
Simply Wall St
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.
more»
02:30 | 6/2/18
StreetInsider.com
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line results from a Phase 2b study of EGP-437 combination product for pain and inflammation in patients having undergone cataract surgery.
more»
02:30 | 6/2/18
GlobeNewswire
WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and ...
more»
00:15 | 13/1/18
Post Analyst
Analyzing the last five market sessions, the stock was able to report 5.65% gains, thus going down by -11.53%, compared with its 200-day moving average of $1.26.
more»
07:45 | 12/1/18
NASDAQ Times
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) that has shown a discernible change in trend levels over the path of recent market activity.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |